Angel Biotechnology Holdings (LSE:ABH) Notes Receivable: £0.00 Mil (As of Sep. 2012)


What is Angel Biotechnology Holdings Notes Receivable?

Angel Biotechnology Holdings LSE:ABH Notes Receivable is £0.00 Mil as of Sep. 2012. The stock has 2 warning signs investors should review.

Angel Biotechnology Holdings's Notes Receivable for the quarter that ended in Sep. 2012 was £0.00 Mil.

Angel Biotechnology Holdings Notes Receivable Related Terms

Angel Biotechnology Holdings Notes Receivable Historical Data

* Premium members only.

The historical data trend for Angel Biotechnology Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Angel Biotechnology Holdings Notes Receivable Chart

Angel Biotechnology Holdings Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec07 Dec08 Dec09 Dec10 Mar12
Notes Receivable
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Angel Biotechnology Holdings Semi-Annual Data
Jun05 Dec05 Jun06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Mar12 Sep12
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Angel Biotechnology Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of £0.00 Mil mean?
Angel Biotechnology Holdings (LSE:ABH) has a Notes Receivable of £0.00 Mil as of Sep. 2012. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Angel Biotechnology Holdings and its competitors.
Is Angel Biotechnology Holdings' Notes Receivable too high?
Angel Biotechnology Holdings' current Notes Receivable is £0.00 Mil.
How does Angel Biotechnology Holdings' Notes Receivable compare to competitors?
Angel Biotechnology Holdings' Notes Receivable of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Angel Biotechnology Holdings and its competitors. Angel Biotechnology Holdings's current Notes Receivable is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Angel Biotechnology Holdings stock overvalued right now?
Angel Biotechnology Holdings (LSE:ABH) has a current Notes Receivable of £0.00 Mil. The current Notes Receivable is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Angel Biotechnology Holdings (LSE:ABH), the current Notes Receivable is £0.00 Mil as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.